Patrick J Heron
CIK 1365617 · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$632.47M
Companies
16
Total Filings
71
Lifetime Open-Market Net
$87.63M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MIRM | Director | 464,713 | $112.23 | $52.15M | $20.35M | 19 | 2026-06-17 |
| ARQT | Director | 59,661 | $28.42 | $1.70M | $9.07M | 16 | 2026-06-12 |
| MBX | Director | 3,927,774 | $60.06 | $235.90M | $10.00M | 4 | 2026-06-05 |
| HilleVax, Inc. (HLVX) Delisted | Director | 8,552,536 | $2.09 | $17.87M | $0 | 4 | 2025-06-25 |
| Imago BioSciences, Inc. (IMGO) Delisted | Director | — | $36.01 | — | $0 | 1 | 2021-07-19 |
| PCVX | Director | 2,309,554 | $54.60 | $126.10M | $4.00M | 3 | 2021-06-03 |
| Iterum Therapeutics plc (ITRM) Delisted | Director | 80,411 | $0.03 | $2.4K | $0 | 5 | 2020-07-06 |
| PASG | Director | 148,862 | $4.57 | $680.3K | $9.90M | 2 | 2020-03-03 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | 10%+ Owner | 1,299,953 | $2.19 | $2.85M | $21.30M | 2 | 2020-01-13 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | 10%+ Owner | 2,571,450 | $64.97 | $167.07M | $8.00M | 1 | 2019-01-22 |
| ANAB | 10%+ Owner | 3,319,224 | $52.11 | $172.96M | $0 | 2 | 2018-05-15 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | Director | 2,668,570 | — | — | $0 | 3 | 2016-01-14 |
| COLL | Director | 1,196,834 | $35.90 | $42.97M | $1.80M | 2 | 2015-09-14 |
| GKOS | 10%+ Owner | — | $151.33 | — | $0 | 1 | 2015-06-30 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 7,782 | $221.38 | $1.72M | $3.20M | 1 | 2015-04-22 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | Director | 0 | — | — | $0 | 4 | 2010-10-28 |
Recent Filings · Page 2 of 8
71 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-02 | MIRM | Mixed | +5,703 | $0 | EDGAR |
| 2025-05-23 | ARQT | Buy (P) | +5,040 | $68.8K | EDGAR |
| 2025-05-19 | ARQT | Buy (P) | +2,520 | $34.3K | EDGAR |
| 2025-05-15 | ARQT | Buy (P) | +8,674 | $119.4K | EDGAR |
| 2025-05-13 | ARQT | Buy (P) | +6,300 | $85.7K | EDGAR |
| 2025-04-30 | HilleVax, Inc. (HLVX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-18 | MIRM | Buy (P) | +549 | $24.2K | EDGAR |
| 2025-03-12 | MIRM | Buy (P) | +2,298 | $99.5K | EDGAR |
| 2025-03-10 | MIRM | Buy (P) | +1,915 | $83.7K | EDGAR |
| 2025-03-06 | MIRM | Buy (P) | +1,602 | $72.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.